Rachel Klemovitch, Assistant Editor10.05.23
Medtronic, leader in healthcare technology, announced the appointment of Paolo Di Vincenzo of the Neuromodulation business, effective October 30.
Formerly Di Vincenzo worked at Smith+Nephew as senior vice president and general manager of US Advanced Wound Management. Prior to his nine years at Smith+Nephew, Di Vincenzo was at Systagenix (then Acelity), Roche Diagnostics, and Becton Dickinson in various marking leadership positions.
“Paolo is a results-driven leader who puts people first, I’m thrilled to have him join this team as Neuromodualtion moves into the era of personalized medicine with sensing technology. He will play a key role in advancing our capabilities in these arias while driving business execution in alignment with Medtronic’s focus on a performance-driven culture,” said Medtronic’s. Neurosciences Portfolio executive VP Brett Wall.
In his position, Di Vincenzo will be responsible for overall strategic direction and day-to-day operations of the Medtronic Neuromodulation business. The Neuromodulation business is run by the Neurosciences Portfolio which is comprised of Pain Interventions and Brain Modulation. These divisions engineer innovative technologies and therapies to help patients relieve pain, reclaim movement, and restore function.
Formerly Di Vincenzo worked at Smith+Nephew as senior vice president and general manager of US Advanced Wound Management. Prior to his nine years at Smith+Nephew, Di Vincenzo was at Systagenix (then Acelity), Roche Diagnostics, and Becton Dickinson in various marking leadership positions.
“Paolo is a results-driven leader who puts people first, I’m thrilled to have him join this team as Neuromodualtion moves into the era of personalized medicine with sensing technology. He will play a key role in advancing our capabilities in these arias while driving business execution in alignment with Medtronic’s focus on a performance-driven culture,” said Medtronic’s. Neurosciences Portfolio executive VP Brett Wall.
In his position, Di Vincenzo will be responsible for overall strategic direction and day-to-day operations of the Medtronic Neuromodulation business. The Neuromodulation business is run by the Neurosciences Portfolio which is comprised of Pain Interventions and Brain Modulation. These divisions engineer innovative technologies and therapies to help patients relieve pain, reclaim movement, and restore function.